OPTN (Option Therapeutics) EBIT: $-0.45 Mil (TTM As of Dec. 2025)


What is Option Therapeutics EBIT?

Option Therapeutics OPTN EBIT is $-0.45 Mil as of Dec. 2025.

Option Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $-0.19 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.45 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Option Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 was -66.26%. Option Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -107.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Option Therapeutics  (AMEX:OPTN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Option Therapeutics's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-0.756 * ( 1 - 0% )/( (1.087 + 1.195)/ 2 )
=-0.756/1.141
=-66.26 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.102 - 0.015 - ( 0 - max(0, 0.015 - 0.636+0))
=1.087

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.206 - 0.011 - ( 0 - max(0, 0.011 - 0.797+0))
=1.195

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Option Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.756/( ( (0 + max(0.621, 0)) + (0 + max(0.786, 0)) )/ 2 )
=-0.756/( ( 0.621 + 0.786 )/ 2 )
=-0.756/0.7035
=-107.46 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.636) - (0.015 + 0 + 0)
=0.621

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.797) - (0.011 + 0 + 0)
=0.786

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Option Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-0.452/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics EBIT Related Terms

Option Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Option Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics EBIT Chart

Option Therapeutics Annual Data
Trend Jun24 Jun25
EBIT
-1.94 -1.22

Option Therapeutics Quarterly Data
Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial -0.11 -0.29 0.00 -0.26 -0.19

OPTN vs : EBIT Comparison

For the Biotechnology subindustry, Option Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Option Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Option Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Option Therapeutics's EV-to-EBIT falls into.


Option Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.45 Mil mean?
Option Therapeutics (OPTN) has a EBIT of $-0.45 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Option Therapeutics.
Is Option Therapeutics' EBIT too high?
Option Therapeutics' current EBIT is $-0.45 Mil.
How does Option Therapeutics' EBIT compare to ?
Option Therapeutics' EBIT of $-0.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Option Therapeutics. Option Therapeutics's current EBIT is $-0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Option Therapeutics stock overvalued right now?
Option Therapeutics (OPTN) has a current EBIT of $-0.45 Mil. The current EBIT is $-0.45 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Option Therapeutics (OPTN), the current EBIT is $-0.45 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Option Therapeutics Business Description

Comparable Companies
Address 680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.